| ||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
Search results for: "N"
Results 231 - 240 of 277 shown below 
|
||||||||
|
||||||||
|
||||||||
|
||||||||
| NPY processing P Bjellerup, E Theodorsson, H Jörnvall and P Kogner Limited neuropeptide Y precursor processing in unfavourable metastatic neuroblastoma tumours doi:10.1054/bjoc.2000.1234 Abstract | Full article | PDF |
||||||||
| NQO1 H-J Menzel, J Sarmanova, P Soucek, R Berberich, K Grünewald, M Haun and H-G Kraft Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations advance online publication, 2004-04-27 00:00:00.000; doi:10.1038/sj.bjc.6601779 Abstract | Full article | PDF A Begleiter, M K Leith, J A Thliveris and T Digby Dietary induction of NQO1 increases the antitumour activity of mitomycin C in human colon tumours in vivo advance online publication, 2004-10-05 00:00:00.000; doi:10.1038/sj.bjc.6602171 Abstract | Full article | PDF G A Choudry, P A Hamilton Stewart, J A Double, M R L Krul, B Naylor, G M Flannigan, T K Shah, J E Brown and R M Phillips A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9 doi:10.1054/bjoc.2001.2056 Abstract | Full article | PDF |
||||||||
| NS-398 T Toyoshima, R Kamijo, K Takizawa, K Sumitani, D Ito and M Nagumo Inhibitor of cyclooxygenase-2 induces cell-cycle arrest in the epithelial cancer cell line via up-regulation of cyclin dependent kinase inhibitor p21 doi:10.1038/sj.bjc.6600183 Abstract | Full article | PDF P Ricchi, T Di Matola, G Ruggiero, D Zanzi, A Apicella, A di Palma, M Pensabene, S Pignata, R Zarrilli and A M Acquaviva Effect of non-steroidal anti-inflammatory drugs on colon carcinoma Caco-2 cell responsiveness to topoisomerase inhibitor drugs doi:10.1038/sj.bjc.6600289 Abstract | Full article | PDF |
||||||||
| NSAID M Gago-Dominguez, J-M Yuan, J E Castelao, R K Ross and M C Yu Regular use of analgesics is a risk factor for renal cell carcinoma doi:10.1038/sj.bjc.6690728 Abstract | Full article | PDF S A Khuder and A B Mutgi Breast cancer and NSAID use: a meta-analysis doi:10.1054/bjoc.2000.1709 Abstract | Full article | PDF |
||||||||
| NSAIDs P Ricchi, R Zarrilli, A di Palma and A M Acquaviva Minireview: Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy doi:10.1038/sj.bjc.6600829 Abstract | Full article | PDF H T Sørensen, S Friis, B Nørgård, L Mellemkjær, W J Blot, J K McLaughlin, A Ekbom and J A Baron Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study doi:10.1038/sj.bjc.6600945 Abstract | Full article | PDF H J M Smartt, D J E Elder, D J Hicks, N A Williams and C Paraskeva Increased NF-  B DNA binding but not transcriptional activity during apoptosis induced by the COX-2-selective inhibitor NS-398 in colorectal carcinoma cells
doi:10.1038/sj.bjc.6601266 Abstract | Full article | PDF F V N Din, L A Stark and M G Dunlop Aspirin-induced nuclear translocation of NF B and apoptosis in colorectal cancer is independent of p53 status and DNA mismatch repair proficiency
advance online publication, 2005-03-15 00:00:00.000; doi:10.1038/sj.bjc.6602455 Abstract | Full article | PDF D Mazhar, R Ang and J Waxman COX inhibitors and breast cancer advance online publication, 2006-01-17 00:00:00.000; doi:10.1038/sj.bjc.6602942 Abstract | Full article | PDF I Cheng, X Liu, S J Plummer, L M Krumroy, G Casey and J S Witte COX2 genetic variation, NSAIDs, and advanced prostate cancer risk advance online publication, 2007-07-03 00:00:00.000; doi:10.1038/sj.bjc.6603874 Abstract | Full article | PDF K Akre, A M Ekström, L B Signorello, L-E Hansson and O Nyrén Aspirin and risk for gastric cancer: a population-based case-control study in Sweden doi:10.1054/bjoc.2001.1702 Abstract | Full article | PDF |
||||||||
| NSCLC R Jäger, B List, C Knabbe, B Souttou, D Raulais, T Zeiler, A Wellstein, A Aigner, A Neubauer and G Zugmaier Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients doi:10.1038/sj.bjc.6600202 Abstract | Full article | PDF S Y El Sharouni, H B Kal and J J Battermann Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy doi:10.1038/sj.bjc.6601418 Abstract | Full article | PDF N van Zandwijk Tolerability of gefitinib in patients receiving treatment in everyday clinical practice doi:10.1038/sj.bjc.6601477 Abstract | Full article | PDF R Stahel, A Rossi, L Petruzelka, P Kosimidis, F de Braud, M M Bernardo, P-J Souquet, H Soto Parra and C Gridelli Lessons from the 'Iressa' Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations doi:10.1038/sj.bjc.6601479 Abstract | Full article | PDF S Vicent, J M López-Picazo, G Toledo, M D Lozano, W Torre, C Garcia-Corchón, C Quero, J-C Soria, S Martín-Algarra, R G Manzano and L M Montuenga ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours doi:10.1038/sj.bjc.6601644 Abstract | Full article | PDF M A I Abou El Hassan, D C J Mastenbroek, W R Gerritsen, G Giaccone and F A E Kruyt Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL advance online publication, 2004-06-01 00:00:00.000; doi:10.1038/sj.bjc.6601910 Abstract | Full article | PDF V Georgoulias, C Kouroussis, A Agelidou, I Boukovinas, P Palamidas, E Stavrinidis, A Polyzos, K Syrigos, M Veslemes, M Toubis, A Ardavanis, E Tselepatiotis and I Vlachonikolis Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study advance online publication, 2004-07-06 00:00:00.000; doi:10.1038/sj.bjc.6602010 Abstract | Full article | PDF A Onn, M Tsuboi and N Thatcher Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib doi:10.1038/sj.bjc.6602062 Abstract | Full article | PDF P Camus, S Kudoh and M Ebina Interstitial lung disease associated with drug therapy doi:10.1038/sj.bjc.6602063 Abstract | Full article | PDF N L Müller, D A White, H Jiang and A Gemma Diagnosis and management of drug-associated interstitial lung disease doi:10.1038/sj.bjc.6602064 Abstract | Full article | PDF T Higenbottam, K Kuwano, B Nemery and Y Fujita Understanding the mechanisms of drug-associated interstitial lung disease doi:10.1038/sj.bjc.6602065 Abstract | Full article | PDF J Rollin, S Iochmann, C Bléchet, F Hubé, S Régina, S Guyétant, E Lemarié, P Reverdiau and Y Gruel Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer advance online publication, 2005-02-01 00:00:00.000; doi:10.1038/sj.bjc.6602298 Abstract | Full article | PDF V Georgoulias, A Agelidou, K Syrigos, A Rapti, M Agelidou, J Nikolakopoulos, A Polyzos, A Athanasiadis, E Tselepatiotis, N Androulakis, K Kalbakis, G Samonis and D Mavroudis Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study advance online publication, 2005-09-20 00:00:00.000; doi:10.1038/sj.bjc.6602748 Abstract | Full article | PDF Y Ichinose, T Seto, H Semba, K Itoh, Y Inoue, F Tanaka, J Araki, M Tamanoi, H Yamamoto and N Iwamoto UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial advance online publication, 2005-09-20 00:00:00.000; doi:10.1038/sj.bjc.6602781 Abstract | Full article | PDF G Anumanthan, S K Halder, H Osada, T Takahashi, P P Massion, D P Carbone and P K Datta Restoration of TGF-  signalling reduces tumorigenicity in human lung cancer cells
advance online publication, 2005-10-25 00:00:00.000; doi:10.1038/sj.bjc.6602831 Abstract | Full article | PDF S C White, P Lorigan, G P Margison, J M Margison, F Martin, N Thatcher, H Anderson and M Ranson Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer advance online publication, 2006-09-12 00:00:00.000; doi:10.1038/sj.bjc.6603345 Abstract | Full article | PDF N Patel, R Adatia, A Mellemgaard, R Jack and H Møller Variation in the use of chemotherapy in lung cancer advance online publication, 2007-03-06 00:00:00.000; doi:10.1038/sj.bjc.6603659 Abstract | Full article | PDF A Babiak, J Hetzel, F Godde, H-H König, M Pietsch and M Hetzel Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC – a phase II trial advance online publication, 2007-03-13 00:00:00.000; doi:10.1038/sj.bjc.6603683 Abstract | Full article | PDF A G Pallis, A Voutsina, Ar Kalikaki, J Souglakos, E Briasoulis, S Murray, A Koutsopoulos, M Tripaki, E Stathopoulos, D Mavroudis and V Georgoulias 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer advance online publication, 2007-11-13 00:00:00.000; doi:10.1038/sj.bjc.6604068 Abstract | Full article | PDF T J Seng, N Currey, W A Cooper, C-S Lee, C Chan, L Horvath, R L Sutherland, C Kennedy, B McCaughan and M R J Kohonen-Corish DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma advance online publication, 2008-07-01 00:00:00.000; doi:10.1038/sj.bjc.6604452 Abstract | Full article | PDF A Kalikaki, A Koutsopoulos, M Trypaki, J Souglakos, E Stathopoulos, V Georgoulias, D Mavroudis and A Voutsina Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC advance online publication, 2008-08-26 00:00:00.000; doi:10.1038/sj.bjc.6604629 Abstract | Full article | PDF J K Kepa and D Ross DT-diaphorase activity in NSCLC and SCLC cell lines: a role for fos/jun regulation doi:10.1038/sj.bjc.6690268 Abstract | Full article | PDF C McCormick and R I Freshney Activity of growth factors in the IL-6 group in the differentiation of human lung adenocarcinoma doi:10.1054/bjoc.1999.1015 Abstract | Full article | PDF G D Beretta, G Michetti, M O Belometti, G Gritti, A Quadri, P Poletti and R Labianca Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer doi:10.1054/bjoc.2000.1304 Abstract | Full article | PDF H Anderson, P Hopwood, R J Stephens, N Thatcher, B Cottier, M Nicholson, R Milroy, T S Maughan, S J Falk, M G Bond, P A Burt, C K Connolly, M B McIllmurray and J Carmichael Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome doi:10.1054/bjoc.2000.1307 Abstract | Full article | PDF L Boldrini, A Calcinai, E Samaritani, F Pistolesi, A Mussi, M Lucchi, C A Angeletti, F Basolo and G Fontanini Tumour necrosis factor-  and transforming growth factor-  are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL -2-mediated neovascularization
doi:10.1054/bjoc.2000.1345 Abstract | Full article | PDF S Vonlanthen, J Heighway, H J Altermatt, M Gugger, A Kappeler, M M Borner, M van Lohuizen and D C Betticher The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression doi:10.1054/bjoc.2001.1791 Abstract | Full article | PDF M Kawahara, K Furuse, Y Segawa, K Yoshimori, K Matsui, S Kudoh, K Hasegawa and H Niitani Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer doi:10.1054/bjoc.2001.2031 Abstract | Full article | PDF Ö U Ataman, S M Bentzen, M I Saunders and S Dische Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis doi:10.1054/bjoc.2001.2049 Abstract | Full article | PDF |
||||||||
| NSCLC cell lines W Zoli, L Ricotti, M Dal Susino, F Barzanti, G L Frassineti, S Folli, A Tesei, F Bacci and D Amadori Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer doi:10.1038/sj.bjc.6690737 Abstract | Full article | PDF J R Kroep, G Giaccone, C Tolis, D A Voorn, W J P Loves, C J van Groeningen, H M Pinedo and G J Peters Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines doi:10.1054/bjoc.2000.1399 Abstract | Full article | PDF |
||||||||
| NSCLC cells E Giovannetti, V Mey, R Danesi, F Basolo, S Barachini, M Deri and M Del Tacca Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile advance online publication, 2005-02-08 00:00:00.000; doi:10.1038/sj.bjc.6602382 Abstract | Full article | PDF |
||||||||
| NSCLC primary cultures W Zoli, L Ricotti, M Dal Susino, F Barzanti, G L Frassineti, S Folli, A Tesei, F Bacci and D Amadori Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer doi:10.1038/sj.bjc.6690737 Abstract | Full article | PDF |
||||||||
| NSE J-M Boher, J-L Pujol, J Grenier and J-P Daurès Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis doi:10.1038/sj.bjc.6690227 Abstract | Full article | PDF |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
|
|
|
| |||
| Print ISSN: 0007-0920 | Online ISSN: 1532-1827 | © 2008 Cancer Research UK | ||
| |||
| Privacy Policy | |||